Ravi A Madan M.D.
@Dr_RaviMadan
Followers
3K
Following
5K
Statuses
3K
Clinical researcher focused on #ProstateCancer, early recurrence (#BCR) & #immunotherapy. Views are my own & do not represent the National Cancer Institute
Bethesda, MD
Joined June 2016
Thank you @UroToday & DrSartor for the opportunity to discuss a commentary in @JCO_ASCO w/@RickLee6 @EdwinPosadasMD @FatimaKarzai @PChoyke & #EvanYu @fredhutch ⚠️There is danger & no🚫data supporting #PSMA #PET 🩻restaging in #mCRPC #ProstateCancer⚠️ 🔗
PSMA PET in #ProstateCancer: Balancing Sensitivity and Clinical Relevance. @Dr_RaviMadan @theNCI joins Oliver Sartor, MD @MayoClinic to discuss the implications of using PSMA PET scans in #mCRPC. #Watch the full interview on UroToday >
0
7
28
@NickTscherniaMD Agree. But in #ProstateCancer PSA50 decline is marker of efficacy and often reported with those implications. Just good to know that in regimen that include cyclophosphamide… that may be the driver of the of PSA responses in a subset of patients
0
0
1
I’d like to sincerely thank co-authors on this abstract who have graciously referred many interested pts for this study #PSMA+ #BCR #ProstateCancer
@Dr_JeannyAC
@laurasenamd
@RPachynski
@mbilusic
@EdwinPosadasMD
@HelenMoonMD
@ChesnutGregory
@asco #GU25 Accrual continues
Abs#45 @asco #GU25 Prelim data shows near term metastatic progression (conventional imaging) is a rare event in #PSMA+ #BCR #ProstateCancer Are we overtreating pts w/ median age of 70+ based on lack of understanding of #PSMA? This study continues…
0
0
3
Important topic that requires careful consideration from many perspectives. So glad to see this topic debated by excellent thought leaders at a symposium honoring one of the most thoughtful people most of us have known: Dr Felix Feng. #PSMA #Endpoints #TrialDesign #GU25
@EdwinPosadasMD and Mike Morris @mskcc go head to head in debate on whether PSMA Imaging should be a trials endpoint. #FelixFeng symposium @ASCO #GU25
0
2
7
Ab#180 @asco #GU25 Dr. Melissa Abel @melissaabel20
@theNCI
#Radium in PET+ CT/bone scan negative #BCR #ProstateCancer Changes on PET scans & PSA declines observed Rare Gd1/2 toxicity No 🚫anemia or thrombocytopenia (Unlike other studies w/SBRT)
0
3
20
@PaulKRadiation @ASCO @urotoday @PCF_Science @laurasenamd @Dr_JeannyAC @mbilusic @RPachynski @EdwinPosadasMD @HelenMoonMD @FatimaKarzai @davidjeinstein Thanks @PaulKRadiation We hope this data now & as it continues to evolve brings more balance to the conversations about #PSMA+ #BCR #ProstateCancer & what the near term risks of monitoring truly are As per our @asco abs the vast majority of pts defer treatment despite +PSMA
Willingness of pts with BCR w/ +ve 18F-DCFPyL PSMA PET/CT to monitor w/o Rx #ASCO24 @urotoday ⚡️n=86 ⚡️mPSA: 2.55 (range: 0.5-71.6) ⚡️mPSADT: 11 mo (range: 1.2-132.4) ⚡️81.4% White, 13.9% Black, 8% Hispanic ⚡️77 (89.5%) +ve findings, 67 (87%) elected to monitor disease till next scan
0
0
1
#PARP inhibitors in #ProstateCancer will again take center stage at #GU25 @ASCO Here is refresher on some thoughts of the earlier data in #mCRPC
@vanderweelemd @heatherhcheng @FatimaKarzai @urotoday @OncoAlert
0
10
27
Important to note only 34% in control arm got #LU-psma. But is 34 month Vs 26 month OS beyond what I’d expect… maybe? Would be interesting to model data from these trials of those who got sequential Intriguing data to be sure. Congrats @ANZUPtrials #ProstateCancer #GU25
Ab#17 @ASCO #GU25 by #LouiseEmmett👉�OS & HRQoL data from ENZA-p (ANZUP 1901) #prostatecancer👉Lu-177 + enza vs enza👉⬆️OS & HRQoL in poor risk mCRPC👇@MartinStockler @OncoAlert @urotoday @PCF_Science
0
0
3
As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer
@RickLee6 @EdwinPosadasMD
0
4
15
Congratulations to @Dr_JeannyAC Dr. Aragon-Ching and Dr. Beltran @mishabeltran Both huge contributors to #GU #Oncology and @asco
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more:
1
3
14
RT @jamecancerdoc: Remembering @felixfengmd former @NRGonc GU committee Chair @UCSFHospitals at #NRG2025! Friend, colleague and leade…
0
7
0
RT @EllisLab_: Great team effort and some impactful science unwrapping a novel mechanism of #prostatecancer plasticity with a therapeutic s…
0
6
0
RT @CaP_pubs: NXP800 activates the unfolded protein response, altering AR and E2F function to impact castration-resistant prostate cancer g…
0
3
0
RT @brunonahar: Excited to moderate the Prostate Cancer session at @dsui_miami_uro Urology on the Beach 2025 with @sanojpunnen! Great speak…
0
9
0
RT @OncologyNT: 📰 NEWS: New drug hope for prostate cancer patients Read more here: Pictured: Study co-leader Dr A…
0
2
0
RT @DrChoueiri: JUST IN: + pivotal trial for PD-1 in non-muscle invasive bladder cancer (NMIBC): The CREST trial of BCG +/- PD-1 sasanlimab…
0
29
0